The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 5 , Pages 1143-1152 , November 2010

Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium

Read at the 90th Annual Meeting of The American Association for Thoracic Surgery, Toronto, Ontario, Canada, May 1–5, 2010.

  • Michael P. Robich, MD, MSPH

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert School of Medicine, Brown University, Providence, RI
    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Louis M. Chu, MD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert School of Medicine, Brown University, Providence, RI
    • ,
  • Jun Feng, MD, PhD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Rhode Island Hospital, Providence, RI
    • ,
  • Thomas A. Burgess, MA

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Rhode Island Hospital, Providence, RI
    • ,
  • Roger J. Laham, MD

      Affiliations

    • Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Cesario Bianchi, MD, PhD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Rhode Island Hospital, Providence, RI
    • ,
  • Frank W. Sellke, MD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert School of Medicine, Brown University, Providence, RI
    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • Department of Surgery, Division of Cardiothoracic Surgery, Rhode Island Hospital, Providence, RI
    • Corresponding Author InformationAddress for reprints: Frank W. Sellke, MD, Division of Cardiothoracic Surgery, Cardiovascular Research Center, Alpert Medical School, Brown University, 593 Eddy St, APC 424, Providence, RI 02903.

Received 22 April 2010 ,Revised 28 May 2010 ,Accepted 28 June 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by the National Heart, Lung and Blood Institute (F.S.W.) grants RO1HL46716, RO1HL69024, and RO1HL85647; by the National Institutes of Health (M.P.R.) grant 5T32-HL0074; and by the Irving Bard Memorial Fellowship (M.P.R., L.M.C.).

 Disclosures: F.W.S. has research support from Ikaria (Clinton, NJ) and Orthologic (Tempe, Ariz) and is a consultant for Novo Nordisk (Princeton, NJ) and Cubist Pharmaceuticals (Lexington, Mass). F.W.S. is a consultant for the law firms representing Pfizer (Princeton, NJ) in the Bextra/Celebrex litigation, but no funding was received for this study, and there was no consultation or notification regarding this study.

PII: S0022-5223(10)00765-8

doi: 10.1016/j.jtcvs.2010.06.057

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 5 , Pages 1143-1152 , November 2010

Article Tools

* Image Usage & Resolution